Continued Access to RXDX-105
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Ovarian Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/23/2019 |
| Start Date: | December 14, 2018 |
| End Date: | December 2019 |
| Contact: | Alexander Drilon, MD |
| Email: | drilona@mskcc.org |
| Phone: | 646-888-4206 |
RXDX-105 for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring a RET Gene Fusion and a Patient With Ovarian Cancer Harboring a BRAF Gene Mutation
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian
cancer benefit from continued treatment with the study drug, RXDX-105.
cancer benefit from continued treatment with the study drug, RXDX-105.
Inclusion Criteria:
- This individual patient protocol includes treatment for 4 patients previously enrolled
on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):
Exclusion Criteria:
- Any patients other than those described above are excluded.
We found this trial at
1
site
New York, New York 10021
Phone: 646-888-4206
Click here to add this to my saved trials
